April 16, 2019
Meet the Residency Class of 2022
The Department is pleased to announce the incoming group of residents.
The Department is pleased to announce the incoming group of residents.
Leading the trial, Dr. Diane Harper spoke to The Lancet. "This is the first time that we have seen such a high level of HPV and grade 2–3 CIN clearance with a therapeutic vaccine.”
In a new clinical trial, the Tipapkinogen Sovacivec (TS) vaccine completely clears HPV in one-third of cervical precancers.
A recent Wall Street Journal Article draws on work from a team of researchers in U-M Family Medicine